17305-22-5

Basic information

• Product Name: (S)-(+)-3-METHYLPIPERIDINE
• Synonyms: (S)-(+)-3-METHYLPIPERIDINE;(3S)-3-METHYLPIPERIDINE;(S)-(+)-3-Methyl-piperidine, 98%ee, 98%
• CAS NO: 17305-22-5
• Molecular Formula: C₆H₁₃N
• Molecular Weight: 99.17
• Mol File: 17305-22-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 126℃
• Flash Point: 17℃
• Appearance: /
• Density: 0.809±0.06 g/cm3(Predicted)
• PKA: 10.49±0.10(Predicted)
• CAS DataBase Reference: (S)-(+)-3-METHYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-3-METHYLPIPERIDINE(17305-22-5)
• EPA Substance Registry System: (S)-(+)-3-METHYLPIPERIDINE(17305-22-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 17305-22-5(Hazardous Substances Data)

Usage

General Description

(S)-(+)-3-methylpiperidine is a chemical compound that belongs to the class of piperidines, which are heterocyclic organic compounds. It is a chiral molecule, with the (S)-enantiomer being the naturally occurring form. 3-methylpiperidine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, due to its reactivity and versatility. It has also been studied for its potential use in the synthesis of organic compounds and as a building block in the production of various compounds. The compound is soluble in organic solvents such as ethanol and ether, and it can be purchased from chemical suppliers in various purities and quantities for research and industrial applications.

Upstream product

• 626-56-2 3-Methylpiperidine 
• 15520-10-2 2-methylcadaverine 
• 737760-90-6 (S)-4-isopropyl-3-(5-methylpyridin-2-yl)oxazolidin-2-one 

Downstream Products

• 109152-48-9 (+)-(S)-N-benzoyl-3-methylpiperidine 
• 37675-27-7 (-)-(R)-N-benzoyl-3-methylpiperidine 
• 109069-00-3 4-((3-methylpiperidin-1-yl)sulfonyl)aniline 

Relevant articles and documents

Acylative kinetic resolution of racemic methyl-substituted cyclic alkylamines with 2,5-dioxopyrrolidin-1-yl (: R)-2-phenoxypropanoate

The diastereoselective acylation of a number of racemic methyl-substituted cyclic alkylamines with active esters of 2-phenoxypropanoic acid was studied in detail. The ester of (R)-2-phenoxypropanoic acid and N-hydroxysuccinimide was found to be the most selective agent. The highest stereoselectivity was observed in the kinetic resolution of racemic 2-methylpiperidine in toluene at -40 °C (selectivity factor s = 73) with the predominant formation of (R,R)-amide (93.7% de). To explain the observed stereoselectivity, DFT modelling of the transition states in the reactions of the title acylating agent with 2-methylpiperidine and 2-methylpyrrolidine was performed. The calculated values were in good agreement with experimental data. It has been demonstrated that the acylation proceeds via a concerted mechanism, in which the addition of an amine occurs simultaneously with the elimination of the hydroxysuccinimide fragment. The high stereoselectivity of the (R,R)-amide formation is largely ensured by the lower steric hindrances in the transition states as compared to the formation of (R,S)-amide.

METHOD FOR SYNTHESISING OPTICALLY ACTIVE PIPERIDINES BY THE HYDROGENATION OF OPTICALLY ACTIVE PYRIDINES

The invention relates to a method for preparing optically active piperidines by the hydrogenation of pyridines using a suitable catalyst. Said method enables the preparation of a plurality of piperidine derivatives with high optical purity and in high yields.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Creceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Creceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.